retatrutide liver damage Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care 🧬 BREAKTHROUGH IN LIVER HEALTH?

Weight-loss drug forecasts jump to $150 billion as supply grows, Reuters, May 28, 2024

The company provided relief after the 1936 Johnstown Flood

Genetic predisposition does not predict exact medication response or guarantee outcomes

Key Takeaways: Read also: Oil Sinks ~5%, Dow Jumps 600+ as Trump Halts Iran Strike Pfizer keeps expanding its GLP-1 portfolio in China through its second licensing deal in just a few months Ecnoglutide is a once-weekly injection already approved in China, with a weight management application currently under review Competition in the GLP-1 space is heating up fast, with heavyweights like Novo Nordisk and Eli Lilly already leading the pack Ecnoglutide belongs to a class of drugs known as GLP-1 receptor agonists, the same category as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro

Weeks 12-48+: Progressive Results Continued steady weight loss toward goal